Scancell Share Discussion Threads

[ivyspivey] 13/1/2021 18:56

Evening,my reply was mainly aimed at EE and when I referred to not being envious of anyone 1M shares in here believe it or not I was not aiming it at anyone specific as I know Inanaco and others are very proud of their holding which is good as it is only them that need to be pleased.
It is aimed at the “ Golden Tickets” on many shares espousing that I take issue with as if it is only one share which is the answer to everyone’s dreams.
It may not appear logical to sell shares when you can afford to wait and believe the prospects are good but that us what I certainly do as I may not like the timeline or simply think there are much better opportunities elsewhere especially within a much shorter timeline.
There has been a huge increase in the share price of many Companys in the last 10 months including here and there us no one “ golden” route to success but many abd just because we take one oath way does not mean different choices are any better or wirse

[inanaco] 13/1/2021 18:54

More evidence of vaccines that are not sterilising

this is "killed Virus partical" vaccine



A coronavirus vaccine developed by China's Sinovac has been found to be 50.4% effective in Brazilian clinical trials, according to the latest results released by researchers.

It shows the vaccine is significantly less effective than previous data suggested - barely over the 50% needed for regulatory approval.

The Chinese vaccine is one of two that the Brazilian government has lined up.

Brazil has been one of the countries worst affected by Covid-19.

Sinovac, a Beijing-based biopharmaceutical company, is behind CoronaVac, an inactivated vaccine. It works by using killed viral particles to expose the body's immune system to the virus without risking a serious disease response.

Several countries, including Indonesia, Turkey and Singapore, have placed orders for the vaccine.

What do we know about China's Covid-19 vaccines?
How do I know the Covid vaccine is safe?
Last week researchers at the Butantan Institute, which has been conducting the trials in Brazil, announced that the vaccine had a 78% efficacy against "mild-to-severe" Covid-19 cases.

But on Tuesday they revealed that calculations for this figure did not include data from a group of "very mild infections" among those who received the vaccine that did not require clinical assistance.

With the inclusion of this data, the efficacy rate is now 50.4%, said researchers.

But Butantan stressed that the vaccine is 78% effective in preventing mild cases that needed treatment and 100% effective in staving off moderate to serious cases.

The Sinovac trials have yielded different results across different countries.

Last month Turkish researchers said the Sinovac vaccine was 91.25% effective, while Indonesia, which rolled out its mass vaccination programme on Wednesday, said it was 65.3% effective. Both were interim results from late-stage trials.

[inanaco] 13/1/2021 18:04

Scancell will have the data and i am informed they will test the variant "actual" Virus against the vaccine serum induced by SN14

[emptyend] 13/1/2021 17:50

The game-changer here will be if Covidity can get into the mix for testing in challenge trials.....I'm sure some 2nd gens will....

[inanaco] 13/1/2021 17:32

Highly contagious new variants of coronavirus will emerge more frequently and spur further infection waves such as those threatening to overwhelm hospitals in the UK and South Africa, one of the world’s leading infectious disease experts has warned.

Salim Abdool Karim, chairman of South Africa’s Covid-19 ministerial advisory committee, also said it was too early to know the extent to which existing vaccines would provide immunity to the new variants.

Scientists around the world have been alarmed by the rapid spread of the new 501.v2 variant first detected in South Africa and the equally infectious B.1.1.7 variant that has led to a surge in cases in the UK. Other variants have emerged recently in Brazil and Japan.

Prof Abdool Karim, the epidemiologist who led South Africa’s fight against HIV/Aids, explained that viruses evolved as they infected people with partial immunity in order to escape recognition by their antibodies.

“We’re going to see this occur more commonly now than in 2020, as we vaccinate and as more people are infected,” he said in an interview with the Financial Times.

The epidemiological finding of increased transmissibility was supported by “biological evidence showing the 501.v2 variant binds more readily and more strongly to human cells”, added Prof Abdool Karim.

--------------------------------------------------------------------------------

any day now ... one of these variants are going to break tolerance of the spike protein vaccines making them weaker and weaker

i would put money on it ......... better buy scancell as Betfred would not give me odds

[inanaco] 13/1/2021 15:25

hope you are watching Ronnie V Ding

unbelievable skill

[inanaco] 13/1/2021 14:25

I see Tosh has done a risk profile ...

Like asking a Bin Man to be a Brain Surgeon i suppose

[inanaco] 13/1/2021 14:17

Ivy nobody is dismissive of anybody's position

except Tosh with mine

when you sold last year i was OK with it, i said at the Time at-least if your not happy do something .. and you did

but look at those that have just held and moaned about it

Gazza and Tosh ...

maybe i should add

if you are sitting with no risk ie freebies ........ why would you even bother to moan ...

I wonder

gazza with his 14.7p average at that time maybe had a reason

but Tosh .... ? maybe freebies with an average .... is a higher average than claimed

[tosh123] 13/1/2021 13:56

Great post Ivy.

[ivyspivey] 13/1/2021 13:31

Hi EE,
Apologies for thinking you were referring to here but my sentiment remains the same in that no matter how much the potential I don’t believe you can blame anyone for selling as even if the share they are selling has a material rerate there are there still rationale reasons for selling imo.
The people judging never take into account where that overdone May reinvest elsewhere.
The timescale for the rerate is often much longer.
The SPmin the short term may go the opposite
The short term taking if profit may just suit someone’s financial position,trading style or risk attitude.
The history of SCLP highlights certainly a couple of these points.
I am very optimistic of the prospects here as I am elsewhere about other stocks.I retain a core and even smaller trading pot but if this doubled tomorrow it would make no difference to me at all.
I don’t envy those with 1M shares and sure like many if I wanted that number I would buy them but much prefer my trading/ investing strategy or again if I thought I coukd do better by going all in here I would do it.
As we know there are no certainty’s in anything and we all make individual decisions and should not be dismissive of anyone else’s actions

[tosh123] 13/1/2021 13:25

There are risks in every aspect of life and investing, to state otherwise is total rubbish and just reinforces your total lack of understanding or grasp of reality.

Go away you silly little man, you have proven ( once again ) that you're bonkers.

Why, after all these years if there are no risks, does scib1 still sit on the shelf gathering dust ?
Why is it not being given to sufferers ?
Why has no one monetised it ?
Why has a big pharma not bought it ?
Why has there not been a queue of companies lined up in a bidding war ?

As for failure, all i need to say to answer that is, when was the last patient treated with scib1 ?
How many people have died since.
Also, it wasn't 100% effective, therefore, by definition, there are risks.

You just continue to make yourself look stupid. No one else needs to get involved, you manage it all by yourself.

[tosh123] 13/1/2021 10:47

Gazza,
he's said a lot of things over the last 9 years ... about 100% of them have been wrong !

If people listened to what he said, they would now be holding very expensive stock... oh .... hang on.

Buy and hold at 45p ... £1 tomorrow ... £8 on the horizon ... there's no risk here ... the company won't be raising any more money ... we're minted ... just a few of the classic things that the idiot has said... there's plenty more as well.

[inanaco] 13/1/2021 10:35

that's because if we Put what you said over the last few years

Nobody would buy ... and you didn't !!

[gazza] 13/1/2021 10:30

It's a shame we don't put 1p on the share price every time Inan says:
"what i said"
We'd be minted!

[inanaco] 13/1/2021 10:24

This falls back into what i said 10 months ago

For Scancell a virus its a step down in its ability and for its products

i made a difficult to treat list and because Cancer escapes the immune system Scancell had to develop vaccines that interacted beyond what a natural immune response could achieve far higher than what is required for a virus

as its turned out the Virus is a very easy target for vaccines, that has been proven by these High Efficacy rates for the current approved vaccines

The massive advantage scancell has is that we are Direct and Cross presented to Dendritic cell via effectively the adaptive system, basically Scancells Plasmid produces antibodies which is why you get these potent response its all about Signalling the high signalling rates, Keeps the T cell locked on to the APC cell for far longer giving it the High Avidity. The exciting bit is the new avidmab patent has turned the wick up again ......... from existing proved immune responses

every other vaccine out there is reliant on "Antigen take up by APC" you can improve that with Ajuvants to help improve the quality of the t cell engagement

in its pure form that is Moditope ......

AZN use a system that encodes the cell infected by the vaccine to produce the antigen ie the structure of the spike protein

moditope you inject only the protein but that is linked directly to the adjuvant
which is then taken up by the APC so the area around the injection site is not flooded with adjuvant but only the protein via this linker technology, you may consider if its so simple why has it taken so long to manufacture ...

soluble ... the most potent peptide for Moditiope is also hydrophobic

Hydrophobic literally means “the fear of water”. Hydrophobic molecules and surfaces repel water. Hydrophobic liquids, such as oil, will separate from water. Hydrophobic molecules are usually nonpolar, meaning the atoms that make the molecule do not produce a static electric field.

and then its linked ...... ISA pharma

once you have wrapped your head around that ........ which for me was a few years ago .. then you can appreciate why i keep buying regardless of market conditions

it only took one party to recognise what i understood ... and Booooom ... that was Diggle

Red Mile is the Icing on the cake .. effectively unlimited funding in the event of successful trials

so this is not about buy sell pick your timings ..... its about how many you own when this all kicks off .... oh its already started

Now at the moment Scancell appears to be making major discoveries which have not been priced in every two years

Homocitrulline Avidmab for instance .....

ATB

[oldnotwise] 13/1/2021 10:13

Interesting Pharma...
Do you rate Martin Diggle above Redmile? If I've misunderstood no worries, but if not could you say why?
ATB

[pharmaboy3] 13/1/2021 09:46

With Martin Diggle as a major shareholder we can be reassured that success will eventually come.He has an amazing track record.Im a LTH in Oxford Biomedica and it took us 10 years to be recognised.He's been there from the beginning.Almost 20 years.Im pretty sure he sold a few OXB shares to increase his holding in SCLP

[inanaco] 13/1/2021 09:34

I won't say anything .........

OMG ....

welcome to the "Cosy Club" ONW

[oldnotwise] 13/1/2021 09:31

Gaz,
the point I was trying to make was IMO FWIW there has been a sea change in the Scancell situation. We are now funded (and the most immediate likely trial is/likely will be funded as a separate endeavour), the platforms have likely been bought towards trial readiness (they better had be since Lockdowns/Covid have provided a great deal of time for such development) and since the entire industry has been hamstrung to some degree by the Pandemic, played correctly Scancell has a great outlook on all fronts in the medium/long term on its core business, and that same optimistic outlook shorter term through Covidity.
As a result I think (again FWIW) that Scancell is in the best position its ever been in in the Short,Medium and Long terms.
That makes me think that now we might be hopeful of a reversal from the eight/nine year downtrend to one of upward moves with smaller retraces. rather than the downward moves with the lesser recoveries.
We also have Interested and Finacially astute Institutional backers who certainly don't invest (and I use the word advisedly) in companies without having assessed the likely future development and commercial possiblilties for their products.
Scancell has a broad spread of IP and a globally saleable immediate vaccine that all need to be proved.
Anyone want to bet that Covidity isn't the first of the products to produce Data?
If it does become the first to produce trial Data (and to me that seems likely) then it seems to me that we are a Covid stock with (other) benefits.
that's whay I think Scancell looks the most exciting stock in my portfolio on a medium term view.
AIMO
DYOR
ATB

[gazza] 13/1/2021 08:59

Ah yes, it's easy to get out the backward focusing binoculars and identify who have been nuts for selling and those who have been genius for buying. As far as Scancell goes, those who have been "in and out" will likely be showing far better returns than those who have sat tight for the past few years.

[emptyend] 13/1/2021 08:46

Ivy,"You ask why do people sell when rerating will come and ONW gave a very good response"I didn't "ask" that in relation to Scancell in fact. That was a quote from my comment concerning another share where two-thirds of shareholders had bought 4 months previously based on firm expectations for 2021 and yet they were selling and crystallising losses of 20%. Nuts on any measure.....as the subsequently doubling of the share price suggests.However, the point of mentioning that example here was to illustrate that material moves can happen without warning. Those who believe that they can trade in and out ad infinitum may be mistaken.Most of us operate in different ways in different circumstances. One cannot be dogmatic either way that one way "works" better than others. For example, momentum traders buying the dips have driven US tech stocks and bitcoin in recent weeks/months......and that is in the process of a sharp reverse, I think.

[oldnotwise] 13/1/2021 08:02

16.311/16.47

[gooosed] 12/1/2021 23:01

"So, like buses, vaccine approvals, in the UK at least, seem to come in threes. First Pfizer/BioNtech, then Oxford/AstraZeneca and now Moderna have been given authorisation to be rolled out across the country. But, Britain, for the moment, is going it alone deciding to postpone second doses to up to 12 weeks. Is this the right thing to do? It’s a controversial question, and one Tim Harford asks a panel of guests: Professor Beate Kampmann, Professor Akiko Iwasaki and Professor Sir David Spiegelhalter on this week’s How To Vaccinate The World."